title: Vaccines as a global imperative--a business perspective.
abstract: During the past thirty years, vaccines have experienced a renaissance. Advances in science, business, and distribution have transformed the field to the point where vaccines are recognized as a "best buy" in global health, a driver of pharmaceutical industry growth, and a key instrument of international development. With many new vaccines available and others on the horizon, the global community will need to explore new ways of ensuring access to vaccines in developing nations. So-called tiered pricing, which makes vaccines available at different prices for countries at different levels of economic development; innovative financing mechanisms such as advance market commitments or offers of long-term and high-volume contracts to vaccine producers; and technology transfers such as sharing intellectual property and production techniques among companies and countries can all play a part in bringing new life-saving vaccines for pneumonia, rotavirus, malaria, and other diseases to developing countries.
authors.affiliation: GlaxoSmithKline Biologicals, Rixensart, Belgium. jean.stephenne@gskbio.com
authors.forename: Jean
authors.initials: J
authors.lastname: Stéphenne
mesh_terms: D003132:Commerce; D003906:Developing Countries; D004345:Drug Industry / Q000191:economics; D014943:Global Health; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D014612:Vaccines / Q000191:economics / Q000600:supply & distribution*
chemical_list: D014612:Vaccines